1980 Volume 28 Issue Supplement6 Pages 45-67
Bacteriological evaluation of a new cephalosporin for injection, cefoperazone (CPZ, T-1551), was conducted in comparison with cefazolin and cefmetazole.
CPZ exhibited a broad antibacterial spectrum covering gram-positive and gramnegative bacteria similar to that of cefazolin and cefmetazole.
CPZ showed superior antibacterial activity against gram-negative bacteria including Neisseria gonorrhoeae, β-lactamase induced bacteria and Pseudomonas aeruginosa than cefazolin and cefmetazole.
CPZ showed a dose-response bactericidal activity against Escherichia coli, Klebsiella pneumoniae and Serratia marcescens, and showed an almost similar activity against Pseudomonas aeruginosa as carbenicillin.
CPZ had an excellent therapeutic effect against mice experimentally infected with susceptible and resistant bacteria to cefazolin, i.e., CPZ's activity against Escherichia coli and Klebsiella pneumoniae was superior to cefazolin and cefmetazole, and also superior to carbenicillin against Pseudomonas aeruginosa, which means that the effectiveness of CPZ was confirmed in vivo as well as in vitro.
CPZ had a therapeutic effect against experimental infections with Proteus inorganii and Serratia marcescens similar to cefmetazole and superior to cefazolin, but against Proteus vulgaris inferior to cefmetazole.
